...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.
【24h】

Postjunctional alpha(2C)-adrenoceptor contractility in human saphenous vein.

机译:大隐静脉中的结后α(2C)-肾上腺素受体收缩性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The postjunctional alpha(2)-adrenoceptor-mediated contractility was characterized in human saphenous vein derived from coronary artery bypass graft surgery. Human saphenous vein contracted to alpha(2)-adrenoceptor selective agonists BHT-920 (5,6,7,8-Tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine dihydrochloride; pD(2)=6.7+/-0.1) and UK 14,304 (5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; pD(2)=7.2+/-0.1). BHT-920-induced contractions were inhibited by the alpha(2)-adrenoceptor antagonist yohimbine (17-Hydroxy-yohimban-16-carboxylic acid methyl ester hydrochloride; pA(2)=8.7+/-0.5), but not by the alpha(1)-adrenoceptor antagonist prazosin (1-[4-Amino-6,7-dimethoxy-2-quinazolinyl]-4-[2-furanylcarbonyl]-piperazine hydrochloride; 300 nM). In contrast, prazosin (pK(b)=7.9+/-0.2) potently antagonized contractions elicited by the alpha(1)-adrenoceptor agonist phenylephrine ((R)-3-Hydroxy-alpha-[(methylamino)methyl] benzenemethanol hydrochloride; pD(2)=4.9+/-0.1), indicating that both alpha(2)- and alpha(1)-adrenoceptor evoke human saphenous vein contractions. Functional antagonist activity estimates (pA(2) or pK(b)) obtained for the alpha-adrenoceptor antagonists ARC 239 (2-[2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride), WB 4101 (2-(2,6-Dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride) and HV 723 (alpha-ethyl-3,4,5-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy) ethyl)amino)propyl)benzeneacetonitrile) against BHT-920-induced human saphenous vein contractions were 7.0+/-0.6, 8.3+/-0.6 and 7.7+/-0.3, respectively. The alpha(2)-adrenoceptor subtype affinities (pK(i)) obtained in recombinant human alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor competition binding assays were 8.6, 8.3 and 8.6 for yohimbine; 6.3, 8.4 and 7.0 for ARC 239; 8.4, 7.5 and 8.4 for WB 4101 and 7.5, 7.4 and 7.9 for HV 723, respectively. Taken together, the binding and functional antagonist activity estimates obtained in these investigations indicate that alpha(2C)-adrenoceptor is the predominant postjunctional alpha(2)-adrenoceptor subtype in human saphenous vein.
机译:结后α(2)-肾上腺素受体介导的收缩力的特征是来源于冠状动脉搭桥手术的人大隐静脉。人大隐静脉收缩到α(2)-肾上腺素受体选择性激动剂BHT-920(5,6,7,8-四氢-6-(2-丙烯基)-4H-噻唑洛[4,5-d]氮杂-2-胺二盐酸盐; pD(2)= 6.7 +/- 0.1)和UK 14,304(5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; pD(2)= 7.2 +/- 0.1)。 BHT-920诱导的收缩受到alpha(2)-肾上腺素受体拮抗剂育亨宾(17-Hydroxy-yohimban-16-羧酸甲酯盐酸盐; pA(2)= 8.7 +/- 0.5)的抑制,但不受α (1)-肾上腺素受体拮抗剂哌唑嗪(1- [4-氨基-6,7-二甲氧基-2-喹唑啉基] -4- [2-呋喃基羰基]-哌嗪盐酸盐; 300nM)。相反,哌唑嗪(pK(b)= 7.9 +/- 0.2)有效拮抗由α(1)-肾上腺素受体激动剂去氧肾上腺素((R)-3-羟基-α-[(甲基氨基)甲基]苯甲醇盐酸盐引起的收缩。 pD(2)= 4.9 +/- 0.1),表明alpha(2)-和alpha(1)-肾上腺素能受体都引起人隐静脉收缩。为α-肾上腺素受体拮抗剂ARC 239(2- [2-(4-(2-甲氧基苯基)哌嗪-1-基)乙基] -4,4获得的功能拮抗剂活性估计值(pA(2)或pK(b)) -二甲基-1,3-(2H,4H)-异喹啉二酮二盐酸盐),WB 4101(2-(2,6-二甲氧基苯氧基乙基)氨基甲基-1,4-苯并二恶烷盐酸盐)和HV 723(α-乙基-3,4,针对BHT-920诱导的人大隐静脉收缩的5-三甲氧基-α-(3-(((2-(2-甲氧基苯氧基)乙基)氨基)丙基)苯乙腈为7.0 +/- 0.6、8.3 +/- 0.6和7.7分别为+/- 0.3。在重组人alpha(2A)-,alpha(2B)-和alpha(2C)-肾上腺素受体竞争结合试验中获得的alpha(2)-肾上腺素受体亚型亲和力(pK(i))为育亨宾,分别为8.6、8.3和8.6; ARC 239的6.3、8.4和7.0; WB 4101分别为8.4、7.5和8.4,HV 723为7.5、7.4和7.9。综上所述,在这些研究中获得的结合和功能拮抗剂活性估计值表明,α(2C)-肾上腺素受体是人隐静脉中主要的结后α(2)-肾上腺素受体亚型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号